vs
Orthofix Medical Inc.（OFIX）与福泰制药（VERX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是福泰制药的1.1倍（$219.9M vs $194.7M），Orthofix Medical Inc.净利率更高（-1.0% vs -3.6%，领先2.6%），福泰制药同比增速更快（9.1% vs 2.0%），过去两年福泰制药的营收复合增速更高（11.4% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
福泰制药是一家总部位于美国马萨诸塞州波士顿的生物制药企业，是全球首批明确采用理性药物设计策略而非组合化学方法的生物技术公司之一。除波士顿总部外，公司还在加利福尼亚州圣迭戈、英国牛津郡米尔顿公园设有三处研发中心，专注于创新药物的研发与商业化。
OFIX vs VERX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$194.7M
营收增速更快
VERX
高出7.1%
2.0%
净利率更高
OFIX
高出2.6%
-3.6%
两年增速更快
VERX
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $194.7M |
| 净利润 | $-2.2M | $-7.0M |
| 毛利率 | 71.1% | 64.8% |
| 营业利润率 | 0.2% | -1.3% |
| 净利率 | -1.0% | -3.6% |
| 营收同比 | 2.0% | 9.1% |
| 净利润同比 | 92.4% | 89.7% |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXVERX
| Q4 25 | $219.9M | $194.7M | ||
| Q3 25 | $205.6M | $192.1M | ||
| Q2 25 | $203.1M | $184.6M | ||
| Q1 25 | $193.6M | $177.1M | ||
| Q4 24 | $215.7M | $178.5M | ||
| Q3 24 | $196.6M | $170.4M | ||
| Q2 24 | $198.6M | $161.1M | ||
| Q1 24 | $188.6M | $156.8M |
净利润OFIXVERX
| Q4 25 | $-2.2M | $-7.0M | ||
| Q3 25 | $-22.8M | $4.0M | ||
| Q2 25 | $-14.1M | $-961.0K | ||
| Q1 25 | $-53.1M | $11.1M | ||
| Q4 24 | $-29.1M | $-67.8M | ||
| Q3 24 | $-27.4M | $7.2M | ||
| Q2 24 | $-33.4M | $5.2M | ||
| Q1 24 | $-36.0M | $2.7M |
毛利率OFIXVERX
| Q4 25 | 71.1% | 64.8% | ||
| Q3 25 | 72.2% | 63.1% | ||
| Q2 25 | 68.7% | 65.7% | ||
| Q1 25 | 62.8% | 63.8% | ||
| Q4 24 | 69.0% | 65.6% | ||
| Q3 24 | 68.7% | 64.8% | ||
| Q2 24 | 67.8% | 63.7% | ||
| Q1 24 | 67.5% | 61.1% |
营业利润率OFIXVERX
| Q4 25 | 0.2% | -1.3% | ||
| Q3 25 | -8.3% | 2.2% | ||
| Q2 25 | -7.9% | -2.1% | ||
| Q1 25 | -25.2% | 2.5% | ||
| Q4 24 | -5.3% | -7.3% | ||
| Q3 24 | -9.6% | 2.9% | ||
| Q2 24 | -12.5% | 4.7% | ||
| Q1 24 | -15.6% | -1.0% |
净利率OFIXVERX
| Q4 25 | -1.0% | -3.6% | ||
| Q3 25 | -11.1% | 2.1% | ||
| Q2 25 | -6.9% | -0.5% | ||
| Q1 25 | -27.4% | 6.3% | ||
| Q4 24 | -13.5% | -38.0% | ||
| Q3 24 | -13.9% | 4.2% | ||
| Q2 24 | -16.8% | 3.2% | ||
| Q1 24 | -19.1% | 1.7% |
每股收益（稀释后）OFIXVERX
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.36 | — | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $314.0M |
| 总债务越低越好 | — | $337.5M |
| 股东权益账面价值 | $450.0M | $258.9M |
| 总资产 | $850.6M | $1.3B |
| 负债/权益比越低杠杆越低 | — | 1.30× |
8季度趋势，按日历期对齐
现金及短期投资OFIXVERX
| Q4 25 | $82.0M | $314.0M | ||
| Q3 25 | $62.9M | $313.5M | ||
| Q2 25 | $65.6M | $284.4M | ||
| Q1 25 | $58.0M | $270.4M | ||
| Q4 24 | $83.2M | $296.1M | ||
| Q3 24 | $30.1M | $279.0M | ||
| Q2 24 | $26.4M | $325.5M | ||
| Q1 24 | $27.0M | $56.1M |
总债务OFIXVERX
| Q4 25 | — | $337.5M | ||
| Q3 25 | $157.2M | $336.9M | ||
| Q2 25 | $157.0M | $336.3M | ||
| Q1 25 | $156.9M | $335.8M | ||
| Q4 24 | $157.0M | $335.2M | ||
| Q3 24 | $118.5M | $334.7M | ||
| Q2 24 | $118.0M | $334.1M | ||
| Q1 24 | $118.2M | $46.0M |
股东权益OFIXVERX
| Q4 25 | $450.0M | $258.9M | ||
| Q3 25 | $442.5M | $264.5M | ||
| Q2 25 | $458.3M | $248.0M | ||
| Q1 25 | $458.3M | $200.5M | ||
| Q4 24 | $503.1M | $179.4M | ||
| Q3 24 | $525.9M | $259.0M | ||
| Q2 24 | $546.0M | $233.1M | ||
| Q1 24 | $570.3M | $250.1M |
总资产OFIXVERX
| Q4 25 | $850.6M | $1.3B | ||
| Q3 25 | $832.6M | $1.2B | ||
| Q2 25 | $837.2M | $1.2B | ||
| Q1 25 | $823.1M | $1.2B | ||
| Q4 24 | $893.3M | $1.2B | ||
| Q3 24 | $867.9M | $1.2B | ||
| Q2 24 | $882.0M | $1.0B | ||
| Q1 24 | $906.0M | $755.8M |
负债/权益比OFIXVERX
| Q4 25 | — | 1.30× | ||
| Q3 25 | 0.36× | 1.27× | ||
| Q2 25 | 0.34× | 1.36× | ||
| Q1 25 | 0.34× | 1.67× | ||
| Q4 24 | 0.31× | 1.87× | ||
| Q3 24 | 0.23× | 1.29× | ||
| Q2 24 | 0.22× | 1.43× | ||
| Q1 24 | 0.21× | 0.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $42.3M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXVERX
| Q4 25 | $27.7M | $42.3M | ||
| Q3 25 | $12.4M | $62.5M | ||
| Q2 25 | $11.6M | $46.0M | ||
| Q1 25 | $-18.4M | $14.8M | ||
| Q4 24 | $23.7M | $41.1M | ||
| Q3 24 | $11.7M | $41.4M | ||
| Q2 24 | $9.0M | $57.7M | ||
| Q1 24 | $-18.6M | $24.6M |
自由现金流OFIXVERX
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | $-24.3M | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | $10.1M |
自由现金流率OFIXVERX
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | -14.2% | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | 6.5% |
资本支出强度OFIXVERX
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | 38.5% | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | 9.2% |
现金转化率OFIXVERX
| Q4 25 | — | — | ||
| Q3 25 | — | 15.44× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.73× | ||
| Q2 24 | — | 11.18× | ||
| Q1 24 | — | 9.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
VERX
| Cloud Subscriptions | $94.6M | 49% |
| Software Licenses | $71.6M | 37% |
| Service Other | $28.5M | 15% |
